Posts

Aardvark to unblind Phase 3 ARD-101 data early after FDA clinical hold

on

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion to Expand Rare Disease Portfolio with VYKAT XR

on

Aardvark Therapeutics Stock Plunges 54% Following Phase 3 Trial Pause

on

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

on

Acadia Pulls Plug on Prader-Willi Drug After Phase 3 Trial Failure

on

Acadia Halts Development of Nasal Prader-Willi Drug After Phase 3 Failure

on

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR

on